Talamonti M - Search Results

1

Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.

Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M, Chimenti S, Costanzo A. Talamonti M, et al. Br J Dermatol. 2013 Aug;169(2):458-63. doi: 10.1111/bjd.12331. Br J Dermatol. 2013. PMID: 23521149

2

Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.

Costanzo A, Peris K, Talamonti M, Di Cesare A, Fargnoli MC, Botti E, Chimenti S. Costanzo A, et al. Among authors: talamonti m. Br J Dermatol. 2007 Apr;156 Suppl 2:17-23. doi: 10.1111/j.1365-2133.2007.07765.x. Br J Dermatol. 2007. PMID: 17371319

3

Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.

Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S. Papoutsaki M, et al. Among authors: talamonti m. J Am Acad Dermatol. 2007 Aug;57(2):269-75. doi: 10.1016/j.jaad.2006.12.003. Epub 2007 Jun 18. J Am Acad Dermatol. 2007. PMID: 17574299 Clinical Trial.

4

Long-term efficacy of adalimumab in generalized pustular psoriasis.

Zangrilli A, Papoutsaki M, Talamonti M, Chimenti S. Zangrilli A, et al. Among authors: talamonti m. J Dermatolog Treat. 2008;19(3):185-7. doi: 10.1080/09546630701759587. J Dermatolog Treat. 2008. PMID: 18569276 Free article.

5

Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.

Costanzo A, Talamonti M, Spallone G, Botti E, Chimenti MS, Papoutsaki M, Chimenti S. Costanzo A, et al. Among authors: talamonti m. Dermatology. 2009;218(2):146-50. doi: 10.1159/000168086. Epub 2008 Oct 30. Dermatology. 2009. PMID: 18971577

6

Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.

Costanzo A, Talamonti M, Botti E, Spallone G, Papoutsaki M, Chimenti S. Costanzo A, et al. Among authors: talamonti m. Dermatology. 2009;219(1):48-53. doi: 10.1159/000213758. Epub 2009 Apr 16. Dermatology. 2009. PMID: 19372639

7

Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience.

Esposito M, Giunta A, Mazzotta A, Babino G, Talamonti M, Chimenti MS, Chimenti S. Esposito M, et al. Among authors: talamonti m. Int J Immunopathol Pharmacol. 2010 Apr-Jun;23(2):503-9. doi: 10.1177/039463201002300212. Int J Immunopathol Pharmacol. 2010. PMID: 20646345 Free article.

8

The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab.

Papoutsaki M, Talamonti M, Giunta A, Costanzo A, Ruzzetti M, Teoli M, Chimenti S. Papoutsaki M, et al. Among authors: talamonti m. Dermatology. 2010;221 Suppl 1:43-7. doi: 10.1159/000316184. Epub 2010 Aug 9. Dermatology. 2010. PMID: 20733314

9

Efalizumab.

Talamonti M, Spallone G, Di Stefani A, Costanzo A, Chimenti S. Talamonti M, et al. Expert Opin Drug Saf. 2011 Mar;10(2):239-51. doi: 10.1517/14740338.2011.524925. Epub 2011 Jan 10. Expert Opin Drug Saf. 2011. PMID: 21214420 Review.

10

Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.

Talamonti M, Teoli M, Botti E, Spallone G, Chimenti S, Costanzo A. Talamonti M, et al. Dermatology. 2011;222(3):250-5. doi: 10.1159/000326111. Epub 2011 Apr 13. Dermatology. 2011. PMID: 21494026

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

326 results

Search Page

Filters